Cervical cancer remains a significant health burden, especially in low- and middle-income countries, despite advancements in prevention. This review synthesizes recent progress in epidemiology, molecular pathogenesis, diagnostics, and therapeutics. Persistent infection with high-risk human papillomavirus (HPV)—notably types 16 and 18—is the primary cause, promoting carcinogenesis via E6 and E7-mediated tumor suppressor inactivation. Diagnostic tools such as HPV DNA testing and cytological screening have improved early detection, while HPV vaccines continue to reduce incidence rates. Standard treatments include surgery and chemoradiotherapy, though immunotherapy, targeted therapies, and therapeutic vaccines are reshaping management approaches. The article highlights challenges in low-resource settings and explores digital innovations that enhance screening reach and equity. Through literature integration and critical insight, the review provides a framework for precision public health and outlines future directions toward eliminating cervical cancer as a global threat.

Cervical cancer represents a significant global health concern, ranked as the fourth most frequent malignancy among women, particularly affecting those in low- and middle-income countries (LMICs) [1]. It arises primarily due to persistent infection by high-risk types of human papillomavirus (HPV), especially HPV-16 and HPV-18, which initiate oncogenic transformation through viral oncoproteins E6 and E7 [2]. Despite the development of effective screening programs and prophylactic vaccines, cervical cancer continues to exert a heavy socio-economic burden, particularly in regions with limited healthcare infrastructure.

Recent advances in cancer biology have elucidated critical molecular mechanisms underpinning cervical carcinogenesis. This has led to the emergence of targeted therapies, novel immunomodulators, and biomarker-based screening tools, which collectively hold promise for improving patient outcomes [3]. The global health community has responded with initiatives like the World Health Organization’s 90-70-90 campaign to eliminate cervical cancer as a public health issue [4].

This review synthesizes current understanding and recent developments in cervical cancer research, covering epidemiology, etiopathogenesis, diagnostic strategies, therapeutic modalities, and public health measures. It provides a reliable commentary and independent insight based on a thorough analysis of the literature, offering new conceptual frameworks for interpreting disease progression and management.

Epidemiology And Global Burden

According to GLOBOCAN 2020, cervical cancer accounted for 604,127 new cases and 341,831 deaths globally, with over 85% of these occurring in LMICs [5]. The disease disproportionately affects younger women aged 30 to 49 years, impacting workforce productivity and familial structures [6]. HPV prevalence varies geographically due to differences in sexual behavior, screening coverage, and vaccination uptake [7].

Sub-Saharan Africa, South Asia, and parts of Latin America have the highest age-standardized incidence and mortality rates [8]. Immunocompromised individuals, especially those co-infected with HIV, exhibit accelerated progression from cervical intraepithelial neoplasia (CIN) to invasive carcinoma [9].

Barriers such as inadequate infrastructure, cultural stigma, and lack of awareness compound the disease burden. Population-based registries and mobile health technologies are now being used to augment surveillance and improve accessibility to screening services [10].

Etiology And Risk Factors

Persistent infection with oncogenic HPV genotypes is the necessary cause of cervical cancer [11]. HPV-16 and HPV-18 contribute to approximately 70% of cases, with other types like HPV-31 and HPV-45 having minor associations [12]. Transmission occurs via sexual contact, and risk factors include early sexual debut, multiple sexual partners, high parity, and smoking [13].

Other contributing factors include prolonged oral contraceptive use, poor genital hygiene, malnutrition, and genetic susceptibility such as polymorphisms in the p53 gene [14]. Social determinants — like limited education and income — also influence risk by affecting healthcare-seeking behavior [15].

HPV Biology and Carcinogenesis

HPV infects basal epithelial cells through microabrasions, establishing a productive infection that may become persistent. High-risk HPV types encode E6 and E7 oncoproteins which inactivate tumor suppressors p53 and Rb, respectively [16]. This leads to dysregulation of the cell cycle, inhibition of apoptosis, and genomic instability.

Integration of HPV DNA into host genome is a hallmark of malignant progression. Epigenetic alterations, including DNA methylation and histone modification, play critical roles in silencing viral suppressors and activating oncogenes [17]. The host immune system fails to clear persistent infection due to local immunosuppression and evasion mechanisms [18].

Pathogenesis And Tumor Progression

Cervical carcinogenesis is a multistep process: normal epithelium → HPV infection → CIN1 (low grade) → CIN2/3 (high grade) → invasive carcinoma [19]. The duration from infection to cancer can span years, offering a window for intervention. Molecular signatures of progression include upregulation of telomerase activity, angiogenesis, and altered expression of MMPs and VEGF [20].

Studies have shown that inflammation and oxidative stress further contribute to DNA damage and neoplastic transformation [21]. Cancer stem cells and epithelial-mesenchymal transition (EMT) pathways have also been implicated in metastasis and therapeutic resistance [22].

Histopathology And Clinical Staging

The two main histological subtypes are squamous cell carcinoma (~70%) and adenocarcinoma (~25%) [23]. Rare variants include adenosquamous, small-cell, and neuroendocrine carcinomas. The FIGO (International Federation of Gynecology and Obstetrics) staging system was revised in 2018 to include imaging and pathology data [24].

Early-stage disease is often asymptomatic, but advanced cases present with abnormal bleeding, pelvic pain, and urinary symptoms. Biopsies remain critical for definitive diagnosis, with immunohistochemical staining for p16 and Ki-67 used to differentiate precancerous lesions [25].

Screening Modalities and Prevention Strategies

Early detection of cervical precancerous lesions has drastically reduced disease incidence in high-resource countries. The Pap smear, introduced by Dr. George Papanicolaou in the 1940s, remains a cornerstone of cytological screening [26]. More recently, HPV DNA testing has demonstrated superior sensitivity for high-grade CIN lesions and is increasingly used in co-testing protocols [27]. Visual Inspection with Acetic Acid (VIA) offers a low-cost alternative, suitable for LMICs. Innovations such as self-sampling kits and digital cervicography are improving accessibility and accuracy [28].

The most impactful preventive strategy is HPV vaccination. Three vaccines — bivalent (Cervarix), quadrivalent (Gardasil), and nonavalent (Gardasil-9) — target oncogenic HPV strains and have shown up to 90

Cervical cancer encapsulates both the triumphs and failures of global health systems. It is a disease that is eminently preventable, predictable, and treatable — yet continues to devastate vulnerable populations due to systemic inequities and inertia in implementation. The fusion of molecular research, digital diagnostics, and policy innovation presents a unique opportunity to recalibrate strategies.

This review provides a panoramic and nuanced understanding of cervical cancer — from its molecular roots to public health ramifications, offering new conceptual frameworks and actionable insights. Sustained commitment, evidence-informed action, and global solidarity are essential to realize the goal of eliminating cervical cancer as a public health threat.